We chose to minimize the biologic variability of biomarkers of HF, such as NT-proBNP and irisin, because stable HF patients with the same NYHA class and LVEF with sinus rhythm and atrial fibrillation/flutter have enormous differences in serum levels of these molecules. The gene discussed is FNDC5; the disease is hydrops fetalis.